Information Provided By: 
Fly News Breaks for February 25, 2016
PTCT
Feb 25, 2016 | 07:58 EDT
After the FDA refused to review the company's application for Translarna for the treatment of Duchenne muscular dystrophy, PTC spoke with the company's management and expects the FDA to delay approving the drug for a year. The firm does not expect the EU to be influenced by the FDA's decision. It lowered its price target on the name to $111 from $135 but keeps an Outperform rating on the shares.
News For PTCT From the Last 2 Days
PTCT
Apr 25, 2024 | 16:09 EDT
PTCT
Apr 25, 2024 | 16:09 EDT
Reports Q1 revenue $210M, consensus $169.7M. "We are off to a strong start in 2024, with outstanding commercial performance and achievement of all planned clinical and regulatory milestones for the first quarter," said Matthew Klein, M.D., Chief Executive Officer, PTC Therapeutics, Inc. "We remain on track to achieve the many planned 2024 clinical and regulatory milestones, including global regulatory submissions for sepiapterin."
